<DOC>
	<DOCNO>NCT01962441</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability 16 24 week sofosbuvir ( Sovaldi® ; SOF ) + ribavirin ( RBV ) , 12 week SOF+RBV+peginterferon alfa-2a ( Peg-IFN ) treatment-naive treatment-experienced adult chronic genotype 3 hepatitis C virus ( HCV ) infection , treatment-experienced adult cirrhosis chronic genotype 2 HCV infection .</brief_summary>
	<brief_title>SOF ( Sovaldi® ) +RBV 16 24 Weeks SOF+RBV+Peg-IFN 12 Weeks Adults With Genotype 2 3 Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Male female , age great equal 18 year . Confirmed chronic HCV infection . Subjects cirrhosis status assessment ; liver biopsy may require . Genotype 2 subject must cirrhosis liver eligible . Treatmentnaive prior treatment failure ≥12 week interferon base regimen discontinue prematurely due adverse event Infection HCV genotype 2 3 determine Screening Body mass index ( BMI ) great equal 18 kg/m^2 Screening laboratory value within predefined threshold . Liver imaging ( e.g. , ultrasound ) within 6 month Baseline/Day 1 require cirrhotic patient exclude hepatocellular carcinoma ( HCC ) . In event intrahepatic lesion , triple phase CT scan MRI perform exclude HCC . Subject must generally good health determine Investigator . Prior use inhibitor HCV nonstructural protein ( NS ) 5B polymerase Pregnant nursing female male pregnant female partner History clinically significant chronic liver disease . HIV chronic hepatitis B virus ( HBV ) infection . Malignancy exception certain resolve skin cancer . Chronic use systemically administer immunosuppressive agent . Clinicallyrelevant drug alcohol abuse . History solid organ transplantation . Current prior history clinical hepatic decompensation . History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol . Known hypersensitivity interferon , RBV , study investigational medicinal product , metabolite , formulation excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>7977</keyword>
	<keyword>GS-7977</keyword>
	<keyword>PSI-7977</keyword>
	<keyword>Sofosbuvir ( SOF )</keyword>
	<keyword>Pegylated Interferon ( PEG )</keyword>
	<keyword>Ribavirin ( RBV )</keyword>
</DOC>